261953-36-0

Basic information

• Product Name: 6-IODO (1H)INDAZOLE
• Synonyms: 6-IODO (1H)INDAZOLE;6-IODOINDAZOLE;1H-Indazole, 6-iodo-;6-iodo-1h1indazole;261953-36-0
• CAS NO: 261953-36-0
• Molecular Formula: C₇H₅IN₂
• Molecular Weight: 244.03247
• EINECS: 1592732-453-0
• Product Categories: pharmacetical
• Mol File: 261953-36-0.mol
• Article Data: 10

Chemical Properties

• Melting Point: 207.0 to 211.0 °C
• Boiling Point: 358.2°Cat760mmHg
• Flash Point: 170.4°C
• Appearance: Clear colorless to light yellow/Liquid
• Density: 2.082g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.788
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 12.96±0.40(Predicted)
• CAS DataBase Reference: 6-IODO (1H)INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-IODO (1H)INDAZOLE(261953-36-0)
• EPA Substance Registry System: 6-IODO (1H)INDAZOLE(261953-36-0)

Safety Data

• Hazardous Substances Data: 261953-36-0(Hazardous Substances Data)

Usage

Physical Form

Light yellow to Brown powder to crystal

Uses

6-Iodo-1H-indazole is an intermediate used to synthesize inhibitors of Chk1.

InChI:InChI=1/C7H5IN2/c8-6-2-1-5-4-9-10-7(5)3-6/h1-4H,(H,9,10)

Upstream product

• 83863-33-6 5-iodo-o-toluidine 
• 850363-52-9 1-acetyl-6-iodo-1H-indazole 
• 79762-54-2 6-bromo-1H-indazole 
• 7597-18-4 6-nitroindazole 
• 6967-12-0 6-amino-1H-indazole 

Downstream Products

• 281203-98-3 6-(thiophen-3-yl)-1H-indazole 
• 1254714-64-1 C₁₄H₁₁IN₂ 
• 885126-34-1 2-((3-iodo-1H-indazol-6-yl)thio)-N-methylbenzamide 
• 1394117-61-3 4-[1-(6-aminopyrimidin-4-yl)-1H-indazol-6-yl]-2-methylbut-3-yn-2-ol 
• 1394119-31-3 4-(6-iodo-1H-indazol-1-yl)pyrimidin-2-amine 
• 1394117-26-0 4-[1-(2-aminopyrimidin-4-yl)-1H-indazol-6-yl]-2-(1,3-thiazol-2-yl)but-3-yn-2-ol 
• 1394119-32-4 4-(6-iodo-2H-indazol-2-yl)pyrimidin-2-amine 
• 1394119-43-7 4-(6-iodo-1H-indazol-1-yl)-5-nitropyrimidin-2-amine 
• 1394120-83-2 6-(6-iodoindazol-1-yl)-N-(2-methoxypyridin-3-yl)pyrimidin-4-amine 
• 1394120-84-3 6-(6-iodoindazol-1-yl)pyrimidin-4-amine 
• 1394119-36-8 5-chloro-4-(6-iodo-1H-indazol-1-yl)pyrimidin-2-amine 
• 1394117-32-8 4-[1-(2-amino-5-chloropyrimidin-4-yl)-1H-indazol-6-yl]-2-(1,3-thiazol-2-yl)but-3-yn-2-ol 
• 1266386-30-4 6-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole 
• 1266386-38-2 6-iodo-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole 

Relevant articles and documents

A 6 - iodo - 1H - indazole synthesis method

The invention discloses a 6 - iodo - 1 H - indazole synthesis method, the synthetic route shown in the following chart: The formula V compounds as the starting material, in under the action of the iodinating agent and catalyst, replacing V compound after the nucleus of the atom, to get the object product, disclosed by the present invention the above-mentioned process route, effectively overcomes the design defects of existing synthetic route, in order to green, few synthesis steps, high yield, production cycle is short and there is little impurity content of the process route, for the preparation of 6 - iodo - 1 H - indazole compound.

PYRIDONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS

Disclosed in the present application is a compound of formula (I) as defined herein as well as a pharmaceutical composition comprising said compound. Further disclosed in the present application is the use of such pharmaceutical compositions for treating diseases, namely inter alia for use in the treatment of cancer, metabolic, inflammatory, autoimmune and viral diseases. The compounds disclosed herein are inhibitors of MNK1 and/or MNK2 kinases.

Bicyclic aromatic substituted pyridone derivative

Disclosed is a compound represented by the formula (I): Wherein R1 and R2 independently represent a hydrogen atom, a lower alkyl group or the like; X1, X2 and X3 independently represent a methine group or a nitrogen atom; Y1 and Y3 independently represent a single bond, —O— or the like; Y2 represents a lower alkylene group or the like; W1 to W4 independently represent a single bond, a methylene group or the like; L represents a single bond, a methylene group or the like; Z1 and Z2 independently represent a single bond, a C1-4 alkylene group or the like; Ar1 represents an aromatic carbocyclic ring or the like; and Ar2 represents a bicyclic aromatic carbocyclic ring or the like. The compound is useful as a pharmaceutical for a central disease, a cardiovascular disease or a metabolic disease.